Name: | eszopiclone |
---|---|
PubChem Compound ID: | 969472 |
Molecular formula: | C17H17ClN6O3 |
Molecular weight: | 388.808 g/mol |
Synonyms: |
138729-47-2; Eszopiclone; (5S)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methylpiperazine-1-carboxylate; 1-Piperazinecarboxylic acid, 4-methyl-, (5S)-6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl ester; Eszopiclone [USAN:INN]; Estorra (TN); D02624; (plus)-Zopiclone; (S)-Zopiclone; Estorra.
show more » |
Name: | eszopiclone |
---|---|
Name (isomeric): | DB00402 |
Drug Type: | small molecule |
Synonyms: |
Esopiclone
|
Brand: | Estorra, Lunesta |
Category: | Hypnotics and Sedatives |
CAS number: | 138729-47-2 |
Indication: | For the treatment of insomnia |
---|---|
Pharmacology: |
Eszopiclone is a nonbenzodiazepine hypnotic, pyrrolopyrazine derivative of the cyclopyrrolone class and is indicated for the short-term treatment of insomnia. While Eszopiclone is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobut...
show more » |
Mechanism of Action: | The mechanism of action of Eszopiclone is not completely understood. It is thought that Eszopiclone acts on the benzodiazepine receptors as an agonist and interacts with GABA-receptor complexes. |
Absorption: | Rapidly absorbed following oral administration |
Protein binding: | 52-59% |
Biotransformation: | Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation. |
Route of elimination: | Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites. |
Half Life: | 6 hours |
Toxicity: | Side effects include viral infection, dry mouth, dizziness, hallucinations, infection, rash, and unpleasant taste, with this relationship clearest for unpleasant taste depending on doses. |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|